Merkoša sitáhtat
APA-čujuhus (7. p.)
Macaya, I., Roman, M., Welch, C., Entrialgo-Cadierno, R., Salmon, M., Santos, A., . . . Vicent, S. (2023). Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer. Nature Portfolio.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
Chicago-čujuhus (17. p.)
Macaya, Irati, et al. Signature-driven Repurposing of Midostaurin for Combination with MEK1/2 and KRASG12C Inhibitors in Lung Cancer. Nature Portfolio, 2023.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
MLA-čujuhus (9. p.)
Macaya, Irati, et al. Signature-driven Repurposing of Midostaurin for Combination with MEK1/2 and KRASG12C Inhibitors in Lung Cancer. Nature Portfolio, 2023.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
Muitte dárkkistit čujuhemiid riektatvuođa, ovdal go geavahat daid iežat deavsttas.